{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T08:58:46Z","timestamp":1761555526170,"version":"build-2065373602"},"reference-count":49,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"vor","delay-in-days":5,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Archiv der Pharmazie"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    Ovarian cancer remains one of the most lethal gynecological malignancies, underscoring the need for novel therapeutic strategies. In this study, a series of pyrimidine\u2010based nucleobase (\n                    <jats:bold>7\u201314<\/jats:bold>\n                    ) and nucleoside (\n                    <jats:bold>21\u201324<\/jats:bold>\n                    ) analogs were synthesized and evaluated for their potential anticancer activity through poly(ADP\u2010ribose) polymerase (PARP) inhibition. These compounds were tested for in vitro cytotoxicity on ovarian cancer cell lines OVCAR\u20103 and KURAMOCHI. Among the synthesized derivatives\u2014namely, 4\u2010(4\u2010substituted phenylamino)\u20101\u2010cyclopentyl\u20105\u2010(\n                    <jats:italic>H<\/jats:italic>\n                    \/methyl)pyrimidine\u20102(1\n                    <jats:italic>H<\/jats:italic>\n                    )\u2010ones (\n                    <jats:bold>7\u201314<\/jats:bold>\n                    ) and 4\u2010(4\u2010substituted phenylamino)\u20101\u2010(\u03b2\u2010\n                    <jats:sc>d<\/jats:sc>\n                    \u2010ribofuranosyl)\u20105\u2010methylpyrimidine\u20102(1\n                    <jats:italic>H<\/jats:italic>\n                    )\u2010ones (\n                    <jats:bold>21\u201324<\/jats:bold>\n                    )\u2014compound\n                    <jats:bold>8<\/jats:bold>\n                    exhibited the most potent cytotoxic activity. It significantly reduced cell viability in OVCAR\u20103 (IC\n                    <jats:sub>50<\/jats:sub>\n                    \u2009=\u200927.1\u2009\u00b1\u20094.56\u2009\u00b5M) and KURAMOCHI (IC\n                    <jats:sub>50<\/jats:sub>\n                    \u2009=\u200946.2\u2009\u00b1\u20094.87\u2009\u00b5M) cells, outperforming the reference PARP inhibitor olaparib (IC\n                    <jats:sub>50<\/jats:sub>\n                    \u2009=\u200975.8\u2009\u00b1\u20096.1\u2009\u00b5M for OVCAR\u20103, IC\n                    <jats:sub>50<\/jats:sub>\n                    \u2009=\u200984.5\u2009\u00b1\u200911.4\u2009\u00b5M for KURAMOCHI). These results suggest that compound\n                    <jats:bold>8<\/jats:bold>\n                    is a promising lead candidate for further development as an anticancer agent targeting PARP in ovarian cancer.\n                  <\/jats:p>","DOI":"10.1002\/ardp.70117","type":"journal-article","created":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T04:40:15Z","timestamp":1759812015000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeting Ovarian Cancer With Pyrimidine Nucleobase and Nucleoside Analogs: Synthesis, In Vitro Cytotoxic Activity, and Molecular Docking"],"prefix":"10.1002","volume":"358","author":[{"given":"Hilal","family":"Zivali","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Chemistry, Faculty of Pharmacy Ankara University Ankara Turkey"},{"name":"Department of Pharmaceutical Chemistry, Institute of Health Sciences Ankara University Ankara Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8576-2447","authenticated-orcid":false,"given":"Arya","family":"Akda\u011f","sequence":"additional","affiliation":[{"name":"Research, Center for Translational Medicine (KUTTAM) Ko\u00e7 University \u0130stanbul Turkey"},{"name":"Ko\u00e7 University Graduate School of Health Sciences Istanbul Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B\u00fc\u015fra","family":"Demirkan","sequence":"additional","affiliation":[{"name":"Research, Center for Translational Medicine (KUTTAM) Ko\u00e7 University \u0130stanbul Turkey"},{"name":"Ko\u00e7 University Graduate School of Health Sciences Istanbul Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5037-7883","authenticated-orcid":false,"given":"\u0130rem","family":"Durmaz \u015eahin","sequence":"additional","affiliation":[{"name":"Research, Center for Translational Medicine (KUTTAM) Ko\u00e7 University \u0130stanbul Turkey"},{"name":"Ko\u00e7 University Graduate School of Health Sciences Istanbul Turkey"},{"name":"Department of Medical Biology, School of Medicine Ko\u00e7 University \u0130stanbul Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7410-0202","authenticated-orcid":false,"given":"Meral","family":"Tun\u00e7bilek","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry, Faculty of Pharmacy Ankara University Ankara Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,10,6]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-020-0341-y"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcrpr.2017.07.001"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2019.109661"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2019-000983"},{"issue":"15","key":"e_1_2_7_7_1","first-page":"1631","article-title":"DNA\u2010Binding Affinity and Specificity Determine the Phenotypic Diversity in BCL11B\u2010Related Disorders","volume":"41","author":"Hanker A. P.","year":"2023","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"e_1_2_7_8_1","first-page":"123","article-title":"Ovarian Carcinoma Diagnosis","volume":"63","author":"Goff B. A.","year":"2020","journal-title":"Clinical Obstetrics and Gynecology"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1177\/17588359231173183"},{"issue":"7","key":"e_1_2_7_10_1","first-page":"896","article-title":"Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology","volume":"16","author":"Armstrong D. K.","year":"2018","journal-title":"Journal of the National Comprehensive Cancer Network: JNCCN"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2013.12.048"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-050913-022545"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1105535"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1810858"},{"issue":"5","key":"e_1_2_7_15_1","first-page":"529","article-title":"Nucleoside Analogues and Nucleobases in Cancer Treatment","volume":"13","author":"Galmarini C. M.","year":"2017","journal-title":"Lancet Oncology"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2003.11.013"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1074"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2024.129775"},{"issue":"4","key":"e_1_2_7_19_1","first-page":"317","article-title":"A Humanized Yeast Phenomic Model of Deoxycytidine Kinase to Predict Genetic Buffering of Nucleoside Analog Cytotoxicity","volume":"44","author":"Plunkett W.","year":"2019","journal-title":"Cancer Chemotherapy and Pharmacology"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.10096"},{"issue":"30","key":"e_1_2_7_21_1","first-page":"3498","article-title":"Management of Platinum\u2010Resistant, Relapsed Epithelial Ovarian Cancer and New Drug Perspectives","volume":"38","author":"Pujade\u2010Lauraine E.","year":"2020","journal-title":"Journal of Clinical Oncology"},{"issue":"6","key":"e_1_2_7_22_1","first-page":"394","article-title":"Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"68","author":"Torre L. A.","year":"2018","journal-title":"CA: A Cancer Journal for Clinicians"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)62146-7"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11060838"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543770903215883"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2013.12.048"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1080\/15685551.2018.1448232"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0040-4039(00)99971-4"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm00389a005"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2006.11.016"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.orglett.5c01468"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/srep42717"},{"key":"e_1_2_7_33_1","unstructured":"SwissADME accessed March 1 2025 http:\/\/www.swissadme.ch\/."},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0169-409X(00)00129-0"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ddtec.2004.11.007"},{"issue":"7","key":"e_1_2_7_36_1","first-page":"467","article-title":"Oral Druggable Space Beyond the Rule of 5: Insights From Drugs and Clinical Candidates","volume":"13","author":"Doak B. C.","year":"2014","journal-title":"Nature Reviews: Drug Discovery"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/qsar.19960150604"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm801389m"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm020017n"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1020444330011"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1002\/cmdc.202300395"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm000942e"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gky318"},{"key":"e_1_2_7_44_1","unstructured":"ProTox\u2010II accessed March 1 2025 https:\/\/tox-new.charite.de\/protox_II\/."},{"key":"e_1_2_7_45_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2121979119"},{"key":"e_1_2_7_46_1","unstructured":"Schr\u00f6dinger Release 2024\u20102: Maestro Schr\u00f6dinger LLC New York NY 2024."},{"key":"e_1_2_7_47_1","unstructured":"Schr\u00f6dinger Release 2024\u20102: Protein Preparation Wizard Schr\u00f6dinger LLC New York NY 2024."},{"key":"e_1_2_7_48_1","unstructured":"Schr\u00f6dinger Release 2024\u20102: Glide Schr\u00f6dinger LLC New York NY 2024."},{"key":"e_1_2_7_49_1","unstructured":"Schr\u00f6dinger Release 2024\u20102: LigPrep Schr\u00f6dinger LLC New York NY 2024."},{"key":"e_1_2_7_50_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm051256o"}],"container-title":["Archiv der Pharmazie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ardp.70117","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T08:53:43Z","timestamp":1761555223000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ardp.70117"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":49,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1002\/ardp.70117"],"URL":"https:\/\/doi.org\/10.1002\/ardp.70117","archive":["Portico"],"relation":{},"ISSN":["0365-6233","1521-4184"],"issn-type":[{"type":"print","value":"0365-6233"},{"type":"electronic","value":"1521-4184"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"2025-03-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70117"}}